We Don't Like Laundry Detergent Sheets. But These Tiles Impressed Us.
Andrea Barnes/NYT Wirecutter
We put Evo tiles through our typical laundry detergent tests.
First, we test dissolvability in cold water. This test gives us an idea of how well a detergent will perform during cold-water washing, which is one of the most energy-efficient (and environmentally conscious) choices you can make when doing laundry. (Our top laundry detergent picks—powders, liquids, and pods—are all strong performers in cold water.)
Tide Evo tiles passed the test, dissolving fully and quickly (within seconds) in 70 °F water. Tide Evo tiles dissolve within seconds of cold water hitting the washing-machine drum. Andrea Barnes/NYT Wirecutter
To test stain removal, we use two industrial stain tests: a jersey-cotton stain monitor and a linen stain strip. These are soiled with an array of hard-to-clean substances, such as carbon black (a mixture of soot and mineral oil), wine, cocoa, pig blood, sebum (body oil), foundation, peat, grass, baby food, and turmeric.
We added both the stain monitor and the stain strip to a 10-pound load of laundry. Then we tossed in a T-shirt stained with bacon grease and pepperoni pizza to evaluate odor removal. We washed this load with one Evo tile on a cold-water cycle. After the wash cycle ended, we removed the stain tests to air-dry, and we dried the rest of the load—including the shirt stained with bacon grease and pizza—in the dryer.
After the tests dried, we compared them to the stain-test results of similar solid, single-dose detergents: Earth Breeze detergent sheets and Tide Pods Free & Gentle Laundry Detergent. We also folded the dried laundry load, paying close attention to the scent of the laundry itself and making notes of which odors lingered after laundering. Like pods or detergent tablets, Evo tiles can be thrown directly into the drum. Andrea Barnes/NYT Wirecutter
Finally, we repeated our stain and odor protocol, but we used two Evo tiles to see whether doubling up would result in more-powerful cleaning. After an extra 30 minutes, the suds finally dissipated. Andrea Barnes/NYT Wirecutter
Though stain removal was improved when we used two tiles, we don't recommend this method for very stained laundry. The suds from using two tiles filled the machine drum with a deluge of bubbles and lengthened the wash cycle. Instead, you're better off pretreating moderate to severe stains with a separate stain remover.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) — In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. Small Particle Detection : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data. Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.' The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth. For more information, please visit About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080 [email protected]
Yahoo
2 days ago
- Yahoo
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
Improved Sample Throughput, Automation Capabilities and Updated Hardware Design Cytek Aurora™ Evo FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. Small Particle Detection: Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data. Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.' The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth. For more information, please visit About Cytek Biosciences, Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@ Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@ A photo accompanying this announcement is available at in to access your portfolio
New York Times
22-05-2025
- New York Times
I Went to War With Fungus Gnats. This Is the Secret Weapon That Helped Me Win.
When a flying bug comes my way, rational thought goes out the window. With high-pitched squeals and eyes shut, I'll bat the air, hoping to hit a line drive with the helpless creature. But more often than not, it's a swing and a miss. So you can imagine my horror when my indoor plants became infested with hundreds, if not thousands, of fungus gnats in the summer of 2020. My batting average was as low as my mental state as I unsuccessfully feuded against a swarm of tiny flies for weeks. When I thought I had finally gotten rid of them, a new platoon would emerge, ready to pick a fight. Desperation kicked in when every method I tried failed, from insecticides to homemade traps. Until, at last, I hit a walk-off grand slam by staking Garsum Fruit Fly Sticky Traps at the base of each plant. Once they were installed, it took only a few days to strike out the entire army of gnats without breaking a sweat. Since then, these sticky traps have been permanently nestled in the soil of my houseplants and clipped onto the fruit bowls in my kitchen as a frontline defense for keeping unwelcome bugs from invading my home. These sticky fly traps are designed to attract and capture insects that land or crawl onto the surface. Within a week of installing the sticky traps, my coworker Megan Beauchamp managed to capture several gnats hanging around her African violet. Megan Beauchamp/NYT Wirecutter Though fungus gnats are harmless to humans, they can wreak havoc on plants. The larvae live in soil and feed on fungi, organic matter, and occasionally a plant's roots, which can cause a once-thriving anthurium to go dry, lose its vigor, and even decay. It doesn't help that fungus gnats can reproduce surprisingly quickly. Mated females lay 100 to 200 microscopic eggs at a time, and they hatch a mere four to six days later, according to information published by Utah State University Extension and Utah Plant Pest Diagnostic Laboratory. Once the larvae are born, they'll feed (on soil and plant roots) for about 15 days before spinning into a cocoon to transition into adulthood — a speedy five-to-six-day turnaround. In a fit of desperation, I used the adhesive side of a sticky note as my weapon of choice against these gnats, which worked on a small scale, but it led me to believe something better might already be on the market. I was right, and a quick TikTok search pointed me toward my beloved sticky traps — hundreds of videos confirmed their lethal capabilities. The fungus gnats were finally outmatched. A week after I put in the Garsum sticky traps, the flies were completely eradicated — aside from the proof of their lifeless corpses stuck onto the traps. The paper lining keeps the adhesive material from sticking until you're ready to use them. Maki Yazawa/NYT Wirecutter The yellow traps are designed to attract (due to the bright color) and capture (thanks to the super-sticky adhesive) any insect that lands or crawls onto them. They're long-lasting, durable, UV-resistant, and waterproof, so they're ideal for indoor or outdoor use (although I've only used them inside). They come in various designs with simple cutout silhouettes of butterflies, birds, and succulents and, on average, are about the size of an index card. The bottom portion of the trap has a pointed triangular shape, which makes it easier to stake it into the ground or a potted plant. But if you're having trouble inserting one, I've found that piercing the soil first with a butter knife or the plastic mini shovel tool that comes with the traps works well. To install, simply peel off the paper lining on both sides of the trap to reveal the adhesive material. Then, position it upright in the soil so that it's not too close to the plant's stems and leaves but close enough to get in the way of an insect's flight path. These highly effective sticky traps caught dozens of pesky bugs at a time. Even though I don't consider myself the murderous type, I marveled at the sight of the lifeless gnats pinned to the sticky surface. It was as oddly satisfying as taking in the infamous Gum Wall at Pike Place Market in Seattle — equally gross and gratifying. Left: The plants that were affected by the 2020 gnat infestation, after the sticky traps successfully eradicated the bugs. Right: The sticky traps protecting plants in our Long Island City, New York, office. Maki Yazawa/NYT Wirecutter The manufacturer says these sticky traps are also effective against other small airborne insects, like whiteflies, aphids, thrips, midges, leaf miners, mosquitoes, and fruit flies. In the five years that I've used the traps, I've also successfully taken on fruit flies, and I've made a habit of clipping a trap onto the side of my fruit bowl to prevent infestations from occurring. You can also prop them up near a trash can for similar results. I clip a sticky trap on my fruit bowl to trap fruit flies. Maki Yazawa/NYT Wirecutter When I'm not dealing with a full-blown infestation, the traps last several months, and I only toss and replace them once they're too polka-dotted with bugs to work effectively. My only qualm with this product is that the sticky material can get on your fingers, but an alcohol-based hand sanitizer or a few drops of vegetable oil can help soften it enough to rinse away. The manufacturer also notes that the glue can melt when exposed to heat, but I've found that briefly refrigerating the traps can help reconstitute the material. Fortunately, the adhesive doesn't inflict damage on a plant's leaves even if you accidentally touch one with a trap. In my experience, I've been able to carefully peel away any stuck-on leaves with minimal damage. Still, the pros far outweigh the cons, and I appreciate how hands-off this extermination method is. Long gone are the days of risking injury while batting flying insects away. If only solving all my critter concerns could be this easy. But a win's a win, and in my book, these sticky traps are a home run. This article was edited by Megan Beauchamp and Maxine Builder. Here's the best gear for killing flies and other common household pests. Our repellent recommendations are EPA approved, backed by experts, and tested by us. Create a bug-free bubble outdoors with these spatial insect repellents. Bug zappers kill the wrong bugs—to control bugs without a spray repellent, use a spatial repellent or a fan instead.
